339 related articles for article (PubMed ID: 17263000)
1. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
2. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
3. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies to multiple sclerosis treatments.
Rossman HS
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S12-9. PubMed ID: 15253685
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Goodin DS; Hartung HP; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Kappos L; Bogumil T; Knappertz V; Sandbrink R; Beckmann K; White R; Petkau J; Pohl C;
Mult Scler; 2012 Feb; 18(2):181-95. PubMed ID: 21952094
[TBL] [Abstract][Full Text] [Related]
7. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.
Pachner AR; Warth JD; Pace A; Goelz S;
Neurology; 2009 Nov; 73(18):1493-500. PubMed ID: 19884577
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
[TBL] [Abstract][Full Text] [Related]
11. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
12. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
13. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
[TBL] [Abstract][Full Text] [Related]
14. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.
Pozzilli C; Antonini G; Bagnato F; Mainero C; Tomassini V; Onesti E; Fantozzi R; Galgani S; Pasqualetti P; Millefiorini E; Spadaro M; Dahlke F; Gasperini C
J Neurol; 2002 Jan; 249(1):50-6. PubMed ID: 11954868
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.
Malucchi S; Sala A; Gilli F; Bottero R; Di Sapio A; Capobianco M; Bertolotto A
Neurology; 2004 Jun; 62(11):2031-7. PubMed ID: 15184610
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS; Frohman EM; Hurwitz B; O'Connor PW; Oger JJ; Reder AT; Stevens JC
Neurology; 2007 Mar; 68(13):977-84. PubMed ID: 17389300
[TBL] [Abstract][Full Text] [Related]
18. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis.
Petersen B; Bendtzen K; Koch-Henriksen N; Ravnborg M; Ross C; Sorensen PS;
Mult Scler; 2006 Jun; 12(3):247-52. PubMed ID: 16764336
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
[TBL] [Abstract][Full Text] [Related]
20. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
